RPbio알피바이오

RPbio's shares are down sharply over the past year, while trailing earnings have recovered to a modest profit on a small-cap, low-valuation base.

RPbio, a Korean maker of soft capsules for over-the-counter medicines and health supplements on an OEM/ODM basis, reported trailing twelve-month revenue of ₩141.4B and net income of ₩6.7B through H1 2026. The share price closed at ₩5,450 on 19 October 2026, about 25% lower over one year and near the lower half of its 52-week range. The data shows a low P/E of 7 and P/B of 0.4.

What stands out

• Profit has returned: 2025 operating income was ₩5.1B and trailing net income is ₩6.7B, after a loss-making 2024 with negative operating income of about ₩0.7B.
• Revenue grew 9.9% in 2025 to ₩136.2B, but 2024 revenue fell 17.9%, so the top line has been uneven.
• Balance sheet indicators are moderate: liabilities are 46% of equity, cash is ₩10.3B, and borrowings are not reported in the data.
• Trailing free cash flow is ₩8.0B, which is above trailing net income, though the data does not explain the drivers.
• Foreign ownership rose from 1.5% to 1.9% over about 60 days, while 20-day foreign flows were net negative and retail flows were positive.
• The filings list two CEO-change entries (31 March and 30 June 2026) and an independent director change, but the data does not explain the reasons.

What to watch

• The next quarterly or annual filings, to see whether the margin recovery (trailing operating margin 5.3%) holds.
• Further governance filings, since the list shows repeated CEO-change entries in 2026.
• News coverage: the data contains no recent news headlines, so no recent company-specific news is available to review.